ALX Oncology Holdings Inc. announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology ...

IRVINE, Calif.--(BUSINESS WIRE)--CG Oncology, Inc. announced today that interim Phase 3 monotherapy data from the BOND-003 study will be presented as a late-breaking abstract at the upcoming 24 th ...

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, ...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced multiple ...

GFH375 (VS-7375), a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, demonstrated potent anti-tumor activity in pancreatic and colorectal cancer models; Partner GenFleet plans to submit IND ...

There will be presentations on the latest positive progress from AIM’s clinical program in pancreatic cancer, the positive therapeutic effects of AIM’s drug Ampligen on multiple cancer types, and ...

From cutting costs to protecting fragile immune systems, telemedicine (the use of technology to administer health care remotely) can provide an array of benefits to patients with cancer but more must ...

Please provide your email address to receive an email when new articles are posted on . GENEVA — A large percentage of people with colorectal cancer around the world are diagnosed through emergency ...

Data includes results for innovative, proprietary predictive biomarkers developed using company's molecular profiling platform ANN ARBOR, Mich., April 11, 2023 /PRNewswire/ -- Strata Oncology, Inc.

BOSTON, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of ...

Oral presentation of investigator-sponsored study of avutometinib plus defactinib in gynecologic mesonephric cancer, a rare grouping of cancers that generally harbor KRAS mutations “The presentation ...